NewsRoom Articles - Page 1191 of 1254

TuesdayDec 20, 2016 9:17 am

CytoDyn Inc. (CYDY) Targets HIV as its Lead Product, PRO 140, Enters Phase 3 Clinical Development

CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the Washington-based biotech is showing a lot of progress nearing major milestones. PRO 140 is a viral-entry inhibitor, a new class of HIV/AIDS therapies that work by blocking the entry of the human immunodeficiency virus (HIV) to healthy cells. PRO 140 is presently at the Phase 3 clinical trial stage. For the millions worldwide with HIV/AIDS, PRO 140 could offer the promise of a more robust bodyguard from further viral insult with potentially fewer side effects and hardly any toxicity. HIV,…

MondayDec 19, 2016 1:48 pm

Moxian, Inc. (NASDAQ: MOXC) Capitalizing on its Knowledge of Social Media and O2O Market Demographics in China

Moxian, Inc. (NASDAQ: MOXC), a China-based company in the business of providing social media-based marketing and promotion platforms to merchants to help them grow their business, continues to show a thorough understanding of China’s online-to-offline (O2O) and social media market demographics. Although it is hard to establish where China’s O2O market stands, O2O in China covers all kinds of services that are offered by brick-and-mortar establishments. Unlike in the U.S. or Europe, where O2O is often considered to be items purchased online and picked up at a store, in China O2O includes a range of categories. O2O in China takes…

MondayDec 19, 2016 11:58 am

CytoDyn Inc. (CYDY) is “One to Watch”

CytoDyn Inc. (OTCQB: CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection. PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral…

MondayDec 19, 2016 9:17 am

Rennova Health, Inc. (NASDAQ: RNVA) Creating the Next Generation of Health Care

Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does. The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting…

FridayDec 16, 2016 3:27 pm

Singlepoint, Inc. (SING) CEO Comments on Company’s Above-Average Volume in Interview on MoneyTV with Donald Baillargeon

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future. To view this week’s program, visit www.MoneyTV.net In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular,…

FridayDec 16, 2016 1:51 pm

National Waste Management Holdings, Inc. (NWMH) Set to Capitalize on Untapped East Coast Opportunities

The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://nnw.fm/ciT1J) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily…

FridayDec 16, 2016 12:07 pm

Net Element, Inc. (NASDAQ: NETE) Driving Transactions through High-Tech Channels

As one of the fastest-growing technology-driven companies enabling mobile payments and value-added transactional services, Net Element, Inc. (NASDAQ: NETE) is steadily carving out more and more of the global commerce pie. The South-Florida company currently has its sights set on certain key objectives: to empower smart payments through all channels of interaction between merchants and consumers, to establish multiple monetization channels for merchants and to add convenience and speed to everyday commerce. With subsidiaries like PayOnline under its umbrella, it is tactically positioned for substantial growth in the U.S. and in select emerging economies. Over the years, Net Element has…

FridayDec 16, 2016 11:23 am

PharmaCyte Biotech, Inc. (PMCB) Pre-IND Meeting with FDA Makes ATM Funding Possible

For California-based PharmaCyte Biotech, Inc. (OTCQB: PMCB), a light at the end of the pipeline tunnel has become visible as one piece of good news follows another. The approval by the FDA to entertain a Pre-Investigational New Drug (Pre-IND) submission from the company sent PMCB stock soaring to triple its pre-approval value. The resulting market cap made PharmaCyte ‘primarily eligible’ to register securities for sale in an at-the-market (ATM) offering, which it now plans to do through Chardan Capital. To make an ATM offering requires that the issuer be eligible, on a primary basis, to use a shelf registration statement…

FridayDec 16, 2016 9:12 am

Higher Price Target for Ocera Therapeutics (NASDAQ: OCRX) as Hepatic Encephalopathy Treatment Study Moves Forward

An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://nnw.fm/cNkZ1) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis. The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead…

ThursdayDec 15, 2016 3:01 pm

GainClients, Inc. (GCLT) Offering Buyers Simplified Home Search Tools with Comprehensive Results

U.S. home prices are going up steadily, having reached the highest peak in September after 2006’s real estate boom, a growth primarily driven by rising demand and a scarce inventory. The price hike came as a surprise to most real estate professionals, who expected a significant market slowdown in the last few months of 2016. While 2017 is likely to see more moderate growth, the market will continue to expand nonetheless, Realtor.com (http://nnw.fm/f4flB) experts believe, as two of America’s largest generations – Millennials and baby boomers, are reaching a stage in their lives that typically motivates people to buy a…

Financial news and publishing for public and private companies

Contact us: 212.418.1217